Our Team at CPHI India 2023
-
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
-
Mohammad Azharuddin Khan
Vice President, API Sales & Marketing
-
Karun Gaur
Vice President - SEMEA
-
Siddhartha Deshpande
Associate Vice president - SEMEA
-
Netraja Patil
Associate Director, Sales and Marketing - Turkey, Africa
-
Rohit Dash
Director
-
Vishal N Bhojak
Director, Sales and Marketing
-
Susmit Dey
Director, Sales and Marketing
About CPHI India 2023

CPHI India 2023, one of the leading pharmaceutical trade shows, is a highly anticipated event that brings together industry professionals and stakeholders from around the world.
Showcasing the latest innovations, technologies, and trends in the pharmaceutical sector, it serves as an essential platform for networking, knowledge sharing, and business opportunities. Join us in person at the India Expo Centre, Greater Noida, Delhi NCR, from November 28th to 30th, 2023.
At CPHI India, you'll have the opportunity to attend insightful conferences and seminars with renowned experts, foster business collaborations with potential clients, and discuss critical industry topics while witnessing prospects and innovations.
Don't miss out on this transformative event!
Schedule your meeting with our team today and be a part of CPHI India 2023!
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

Our Achievement


免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。